Nova Anchora
PrivateLast Round
Early Funding
Nov 5, 2026
Total Funding Raised
$23M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Nova Anchora operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was an Early Funding round in November 2026.
Nova Anchora is a biotechnology company developing corrective protein therapies for dystrophic epidermolysis bullosa.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nova Anchora Comparables
Compare Nova Anchora with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Phoenicis Therapeutics | 88% | |
| Paradigm Therapeutics, Inc. | 86% | |
| BridgeBio Pharma, Inc. | 84% |
For institutional investors. Book with your work email.
Nova Anchora Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Nov 5, 2026 | ||||
| Seed | Apr 29, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nova Anchora Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EB Research Partnership | Early Funding |
| Viking Global Investors | Seed, Early Funding |
| DEBRA Research gGmbH | Seed, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2026
$23M raised, led by Viking Global Investors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 5, 2026
Nova Anchora receives a $23M equity financing led by Viking Global Investors, with participation from DEBRA Research gGmbH, EB Research Partnership, the EB Medical Research Foundation, and Cure EB, to advance NvA-021 through IND-enabling development and an initial clinical proof-of-concept study in Massachusetts on Nov 5th '26.
- is_developingNov 5, 2026
Nova Anchora develops NvA-021, an investigational topical gel containing recombinant human type VII collagen for dystrophic epidermolysis bullosa, and plans IND-enabling studies, clinical-supply manufacturing, an FDA submission, and an initial clinical proof-of-concept study in Massachusetts.
For institutional investors. Book with your work email.
Nova Anchora Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nova Anchora's valuation, stock price, and market status.
Is Nova Anchora a public or private company?
Nova Anchora is a private company.
What is the current stock price of Nova Anchora?
Nova Anchora is a private company, so its shares have no public market price. Caplight tracks Nova Anchora's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nova Anchora worth (valuation)?
Valuation information for Nova Anchora is not publicly available.
Can I buy Nova Anchora stock?
Nova Anchora shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nova Anchora's last funding round?
Nova Anchora's most recent funding round was Early Funding on November 5, 2026.
Who are the main investors in Nova Anchora?
Key investors in Nova Anchora include Viking Global Investors.
Will Nova Anchora IPO soon?
No public IPO plans have been announced for Nova Anchora.
How can I track Nova Anchora secondary market activity?
Caplight tracks bids, offers, and trades in Nova Anchora's shares on secondary markets.